New Delhi, Nov 9 Amneal Pharmaceuticals, Inc. on Tuesday announced it has acquired Puniska Healthcare Pvt. Ltd. for a total value of $93 million, or approximately Rs 700 crore.
The acquisition significantly enhances Amneal's injectables manufacturing infrastructure, capabilities, and capacity to support the US market and serve as a foundation for international markets.
Puniska includes a 2,93,000 square foot manufacturing facility in Ahmedabad, with a number of sterile injectable production lines. Production capabilities include robotic, aseptic and lyophilize vial lines, emulsion line, and large-volume parenteral bag line.
The acquisition also brings to Amneal approximately 550 Puniska employees with key capabilities in injectables manufacturing, R&D and commercialisation.
"Today we are pleased to announce the acquisition of Puniska, and we welcome the Puniska team to the Amneal family. This acquisition is a pivotal step that meaningfully enhances our injectables capabilities for the US market and enables international expansion, including in India, as we look to become a leading player in the global injectables market," said Chirag and Chintu Patel, Co-Chief Executive Officers.
"Puniska's ability to manufacture high volume and complex products will enable Amneal to build on our robust portfolio and pipeline and contribute to the rapid growth in our injectables business, which we project will more than double by 2025."
Dhinal Shah Associates served as advisor to this transaction.
Since establishing local operations in 2008, Amneal has built a large and growing presence in India through over $300 million, or over 2,200 crore rupees, of capital investments and acquisitions. With Puniska, the Company employs more than 4,500 talented employees to support its core global manufacturing and R&D functions across eight facilities in India. This acquisition furthers the Company's commitment to and underscores its confidence in India as it continues to expand in the country and make meaningful contributions to local economies.
Amneal Pharmaceuticals, Inc. headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the US.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor